[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US2684323A - Procaine ascorbate preparation - Google Patents

Procaine ascorbate preparation Download PDF

Info

Publication number
US2684323A
US2684323A US191483A US19148350A US2684323A US 2684323 A US2684323 A US 2684323A US 191483 A US191483 A US 191483A US 19148350 A US19148350 A US 19148350A US 2684323 A US2684323 A US 2684323A
Authority
US
United States
Prior art keywords
procaine
ascorbate
salt
solution
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US191483A
Inventor
Simon L Ruskin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Physiological Chemicals Co
Original Assignee
Physiological Chemicals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Physiological Chemicals Co filed Critical Physiological Chemicals Co
Priority to US191483A priority Critical patent/US2684323A/en
Application granted granted Critical
Publication of US2684323A publication Critical patent/US2684323A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof

Definitions

  • the present invention relates to the preparation of an improved form of the anaesthetic compound procaine and more particularly to the preparation of procaine ascorbate.
  • Procaine is a well known local anaesthetic and is employed in medicine in the form of a salt, usually with an inorganic acid, the hydrochloride being the salt most commonly employed.
  • the use of the known procaine salts has, however, been attended with serious disadvantages. Quite frequently, edema sets in after the anaesthetic has worn off.
  • Procaine is also known to produce convulsions of varying degrees of intensity.
  • procaine in the form of its ascorbic acid (vitamin C) salt.
  • vitamin C ascorbic acid
  • procaine ascorbate can be employed for local anaesthesia and can be used intravenously for the control of muscular spastic states, neuralgia, allergic reactions, control of traumatic pains and the like.
  • the salt is normally neutral in reaction in aqueous solution and is accordingly substantially free from tissue irritation.
  • procaine ascorbate provides a high concentration of the ascorbate radical within the surgical area, so that wound healing is promoted and a firmer union of the surgical areas of the wound results.
  • This is apparently due to the fact that the salt promotes collagen formation.
  • the high level of vitamin C radical which the salt provides directly in the surgical area cannot be matched by oral administration of vitamin C because the latter is diluted by all the body fluids and is also in large part destroyed by intestinal bacteria such as coli, and of the fraction which is absorbed, only a relatively small amount reaches any particular part of the body.
  • procaine ascorbate is a self-detoxifying preparation in that the con vulsant properties of the procaine are neutralized by the ascorbyl radical, so that the toxicity of procaine is practically entirely absent in its ascorbic acid salt.
  • Procaine ascorbate can be injected intramuscularly in areas to be treated surgically; because it is substantially neutral it can be injected intravenously in the treatment of arthritis and traumatic injury. It is also useful intravenously for cardia arrhythmias and simultaneously corrects disturbances in heart rhythm, while the ascorbic radical acts to improve heart muscle function.
  • Procaine ascorbate can be marketed in the form of the solid salt to be mixed with sterilized water prior to use, or in the form of a A;% to 2% aqueous solution.
  • a known procaine salt such as the hydrochloride, nitrate or borate, and an ascorbate of anon-toxic metal, preferably an alkali or alkaline earth metal, like sodium, potassium and magnesium, can be provided in dry, ampouled form to be mixed with the proper amount of water prior to use.
  • procaine base in equimolecular amount with ascorbic acid may similarly be put up in ampoule form, in the dry condition.
  • Example 1 4.27 g. of ascorbic acid in 1000 cc. of water are stirred with 5.73 g. of procaine base.
  • the procaine goes into solution as procaine ascorbate.
  • the solution is filtered and ampouled in corn venient amounts, for example 5 cc. of the 1% solution.
  • To the solution there can be added of sodium bisulphite or of sodium borate as a stabilizer.
  • the solution can also be stabilized with 5% dextrose.
  • Example 2 Equimolecular proportions of procaine base and ascorbic acid in more or less powdered form are 23.6 g. mol) procaine base and 17.6 g. (1 6 mol) ascorbic acid were warmed with about 200 cc. absolute methyl alcohol until solution was complete. The resulting solution was then slow- 1y treated under stirring and cooling with 500 cc. chloroform or acetone. A yellow precipitate was obtained, which hardened on standing overnight in the ice chest. Yield 40 g. or almost quantitative.
  • the salt procaine ascorbate can be obtained also by evaporation of the solution obtained according to Examples 1 and 2.
  • the salt can also be prepared by double decomposition, between, for example, procaine hydrochloride and a combining proportion of sodium ascorbate.
  • the simultaneously produced sodium chloride is unobjectionable and therefore need not be removed from the solution or from the solid product ob tained on evaporation. This is illustrated by the following example:
  • Example 4 To an approximately saturated aqueous solution of procaine hydrochloride containing 27.3 g. of the salt, there is added a concentrated aqueous solution of sodium ascorbate containing 20 g. of such salt. The resulting mixture is concentrated and the precipitated procaine ascorbate is collected, washed and dried. If desired, the whole reaction mixture can be evaporated to dryness since the sodium chloride that is present therein is generally unobjectionable. The dried procaine ascorbate, with or without sodium chloride, can then be packaged in the dry condition, or the reaction solution itself can be ampouled, or a solution of the separated procaine ascorbate.
  • the dry solid procaine ascorbate can also be marketed in the form of a suspension in an injectabl-e vegetable oil, like peanut and sesame oils.
  • an injectabl-e vegetable oil like peanut and sesame oils.
  • mg. can be suspended in 1 cc. of a peanut oil and beeswax mixture wherein the beeswax has the usual proportion to the peanut oil, such as 1:4.
  • the suspension is only slowly absorbed and produces a longer lasting effect than the aqueous solution.
  • a dry, solid preparation consisting essentially of unreacted procaine base and ascorbic acid in equivalent proportions and adapted, on the addition of Water, to form procaine ascorbate.
  • a dry, solid preparation consisting essentially of an inorganic acid salt of procaine and a substantially equimolecular proportion of a non-toxic metal salt of ascorbic acid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

Patented July 20, 1954 PROCAINE ASCORBATE PREPARATION Simon L. Ruskin, New York, N. Y., assignor to Physiological Chemicals Company, New Rochelle, N. Y., a corporation of New York N Drawing. Application October 21,. 1950,
Serial No. 191,483
4 Claims.
The present invention relates to the preparation of an improved form of the anaesthetic compound procaine and more particularly to the preparation of procaine ascorbate.
The present application is a continuation-inpart of my co-pending application Ser. No. 528,612, filed March 29, 1944, now Patent No. 2,606,903, which is in turn a continuation-in-part of my earlier application Serial No. 457,598 filed September 7, 1942, now Patent No. 2,419,230.
Procaine is a well known local anaesthetic and is employed in medicine in the form of a salt, usually with an inorganic acid, the hydrochloride being the salt most commonly employed. The use of the known procaine salts has, however, been attended with serious disadvantages. Quite frequently, edema sets in after the anaesthetic has worn off. As commonly employed in the form of the hydrochloride, and also as the nitrate, it is quite strongly acid in reaction and consequently causes tissue irritation. Procaine is also known to produce convulsions of varying degrees of intensity.
It is the general object of the present invention to provide a combined form of procaine, in which the disadvantages mentioned are overcome. More particularly, it is an object of the invention to provide a salt of procaine, which in addition to being free of the irritating and disturbing efiects encountered with the use of the known procaine salts, is non-toxic and possesses a healing action which has not been encountered with the procaine salts heretofore employed. Other objects and advantages of the invention will appear from the more detailed description hereinafter.
In accordance with the present invention, I provide the procaine in the form of its ascorbic acid (vitamin C) salt. I have found that procaine ascorbate can be employed for local anaesthesia and can be used intravenously for the control of muscular spastic states, neuralgia, allergic reactions, control of traumatic pains and the like. The salt is normally neutral in reaction in aqueous solution and is accordingly substantially free from tissue irritation.
The favorable therapeutic response of procaine ascorbate is apparently due to the fact that it provides a high concentration of the ascorbate radical within the surgical area, so that wound healing is promoted and a firmer union of the surgical areas of the wound results. This is apparently due to the fact that the salt promotes collagen formation. The high level of vitamin C radical which the salt provides directly in the surgical area cannot be matched by oral administration of vitamin C because the latter is diluted by all the body fluids and is also in large part destroyed by intestinal bacteria such as coli, and of the fraction which is absorbed, only a relatively small amount reaches any particular part of the body.
I have found further, that procaine ascorbate is a self-detoxifying preparation in that the con vulsant properties of the procaine are neutralized by the ascorbyl radical, so that the toxicity of procaine is practically entirely absent in its ascorbic acid salt.
Procaine ascorbate can be injected intramuscularly in areas to be treated surgically; because it is substantially neutral it can be injected intravenously in the treatment of arthritis and traumatic injury. It is also useful intravenously for cardia arrhythmias and simultaneously corrects disturbances in heart rhythm, while the ascorbic radical acts to improve heart muscle function.
Procaine ascorbate can be marketed in the form of the solid salt to be mixed with sterilized water prior to use, or in the form of a A;% to 2% aqueous solution. If desired, mixtures of a known procaine salt such as the hydrochloride, nitrate or borate, and an ascorbate of anon-toxic metal, preferably an alkali or alkaline earth metal, like sodium, potassium and magnesium, can be provided in dry, ampouled form to be mixed with the proper amount of water prior to use. Or procaine base in equimolecular amount with ascorbic acid may similarly be put up in ampoule form, in the dry condition.
The following examples illustrate satisfactory ways of preparing procaine ascorbate by way of illustration and are not to be understood as indicating the scope of the invention.
Example 1 4.27 g. of ascorbic acid in 1000 cc. of water are stirred with 5.73 g. of procaine base. The procaine goes into solution as procaine ascorbate. The solution is filtered and ampouled in corn venient amounts, for example 5 cc. of the 1% solution. To the solution there can be added of sodium bisulphite or of sodium borate as a stabilizer. The solution can also be stabilized with 5% dextrose.
For intravenous use, to mg. of the salt in 500 to 1,000 cc. of isotonic aqueous dextrose or saline solution can be administered by slow drip.
Example 2 Equimolecular proportions of procaine base and ascorbic acid in more or less powdered form are 23.6 g. mol) procaine base and 17.6 g. (1 6 mol) ascorbic acid were warmed with about 200 cc. absolute methyl alcohol until solution was complete. The resulting solution was then slow- 1y treated under stirring and cooling with 500 cc. chloroform or acetone. A yellow precipitate was obtained, which hardened on standing overnight in the ice chest. Yield 40 g. or almost quantitative.
The salt procaine ascorbate can be obtained also by evaporation of the solution obtained according to Examples 1 and 2. The salt can also be prepared by double decomposition, between, for example, procaine hydrochloride and a combining proportion of sodium ascorbate. The simultaneously produced sodium chloride is unobjectionable and therefore need not be removed from the solution or from the solid product ob tained on evaporation. This is illustrated by the following example:
Example 4 To an approximately saturated aqueous solution of procaine hydrochloride containing 27.3 g. of the salt, there is added a concentrated aqueous solution of sodium ascorbate containing 20 g. of such salt. The resulting mixture is concentrated and the precipitated procaine ascorbate is collected, washed and dried. If desired, the whole reaction mixture can be evaporated to dryness since the sodium chloride that is present therein is generally unobjectionable. The dried procaine ascorbate, with or without sodium chloride, can then be packaged in the dry condition, or the reaction solution itself can be ampouled, or a solution of the separated procaine ascorbate.
The dry solid procaine ascorbate can also be marketed in the form of a suspension in an injectabl-e vegetable oil, like peanut and sesame oils. Thus, mg. can be suspended in 1 cc. of a peanut oil and beeswax mixture wherein the beeswax has the usual proportion to the peanut oil, such as 1:4. The suspension is only slowly absorbed and produces a longer lasting effect than the aqueous solution.
Iclaim:
1. Procaine ascorbate.
2. A dry, solid preparation consisting essentially of unreacted procaine base and ascorbic acid in equivalent proportions and adapted, on the addition of Water, to form procaine ascorbate.
3. A dry, solid preparation consisting essentially of an inorganic acid salt of procaine and a substantially equimolecular proportion of a non-toxic metal salt of ascorbic acid.
4. A dry mixture of procaine hydrochloride, and a salt of ascorbic acid selected from the group consisting of alkali and alkaline earth metal salts in equivalent proportions.
References Cited in the file of this patent UNITED STATES PATENTS Number Name Date ,187,467 Stuart Jan. 16, 1940 2,259,492 Ruskin Oct. 21, 1941 2,294,937 Ruskin Sept. 8, 194-2 OTHER REFERENCES Stanistreet, Australian Journal of Pharmacy, Sept. 30, 1946, pages 730 to 733.
Ser. No. 373,612, Kok (A. P. C.), published May 11, 1943.

Claims (1)

  1. 2. A DRY, SOLID PREPARATION CONSISTING ESSENTIALLY OF UNREACTED PROCAINE BASE AND ABSORBIC ACID IN EQUIVALENT PROPORTIONS AND ADAPTED, ON THE ADDITION OF WATER, TO FORM PROCAINE ASCORBATE.
US191483A 1950-10-21 1950-10-21 Procaine ascorbate preparation Expired - Lifetime US2684323A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US191483A US2684323A (en) 1950-10-21 1950-10-21 Procaine ascorbate preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US191483A US2684323A (en) 1950-10-21 1950-10-21 Procaine ascorbate preparation

Publications (1)

Publication Number Publication Date
US2684323A true US2684323A (en) 1954-07-20

Family

ID=22705675

Family Applications (1)

Application Number Title Priority Date Filing Date
US191483A Expired - Lifetime US2684323A (en) 1950-10-21 1950-10-21 Procaine ascorbate preparation

Country Status (1)

Country Link
US (1) US2684323A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2459659A1 (en) * 1979-06-23 1981-01-16 Centrala Ind Medicamente Synergistic anticancer compsns. - contg. 4-aminobenzoyl-di:ethyl-aminoethanol, boric acid and ascorbic acid
US4956391A (en) * 1988-08-17 1990-09-11 Sapse Alfred T Protected complex of procaine for the treatment of symptoms from narcotics addiction, tinnitus and alzheimer's disease
US5180839A (en) * 1976-07-01 1993-01-19 Sawyer Philip Nicholas Anti-thrombotic compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2187467A (en) * 1939-02-11 1940-01-16 Lilly Co Eli Cevitamate solution
US2259492A (en) * 1938-05-28 1941-10-21 Simon L Ruskin Therapeutic preparation of bismuth and method of preparing same
US2294937A (en) * 1938-02-26 1942-09-08 Simon L Ruskin Cevitamate compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2294937A (en) * 1938-02-26 1942-09-08 Simon L Ruskin Cevitamate compound
US2259492A (en) * 1938-05-28 1941-10-21 Simon L Ruskin Therapeutic preparation of bismuth and method of preparing same
US2187467A (en) * 1939-02-11 1940-01-16 Lilly Co Eli Cevitamate solution

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180839A (en) * 1976-07-01 1993-01-19 Sawyer Philip Nicholas Anti-thrombotic compounds
FR2459659A1 (en) * 1979-06-23 1981-01-16 Centrala Ind Medicamente Synergistic anticancer compsns. - contg. 4-aminobenzoyl-di:ethyl-aminoethanol, boric acid and ascorbic acid
US4956391A (en) * 1988-08-17 1990-09-11 Sapse Alfred T Protected complex of procaine for the treatment of symptoms from narcotics addiction, tinnitus and alzheimer's disease

Similar Documents

Publication Publication Date Title
DE3875285T2 (en) USE OF SALTS OF N-ACETYLNEURAMIN ACID FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE SWELLING OF THE NOSE MUSCLE SKIN.
DE2530372A1 (en) Oral and topical compsns. for psoriasis treatment - contg. fumaric acid (derivs.) and diluent contg. org. acid salts.
DE2433407A1 (en) SULPHATES OF HYDROXYAETHYL STARCH
US2684323A (en) Procaine ascorbate preparation
US3830824A (en) Physiological organic acid silver allantoinates
GB1487397A (en) Heteropolyanions having antiviral properties
HAJDU et al. Action of ryanodine on mammalian cardiac muscle: Effects on contractility, and reversal of digitalis-induced ventricular arrhythmias
Miller et al. Simultaneous hyperfunction of the thyroid and parathyroid glands
US2294937A (en) Cevitamate compound
Zoll et al. Electrocardiographic changes in rats deficient in vitamin B1
DE2759108A1 (en) USE OF ALPHA -MERCAPTO-BETA-ARYL-ACRYLIC ACIDS IN INCREASING THE ZINC CONTENT IN SERUM AND TISSUE
Miller et al. Electrocardiographic changes following the intravenous administration of magnesium sulfate: III. Combined effect with digitalis
RU2668966C1 (en) Complex salts of acidum acexamicum, stimulating regeneration of bone tissue, accelerating processes of reparative osteogenesis, stimulating mineralization of bone tissue in osteoporosis
US2676961A (en) Procaine-penicillin preparation
US2260870A (en) Medicinal preparation
US2159214A (en) Double salt of calcium ascorbate and calcium acetylsalicylate and process of making same
SU1268167A1 (en) Method of producing strophanthin
Magee et al. Studies on the movements of the alimentary canal: I. The effects of electrolytes on the rhythmical contractions of the isolated mammalian intestine
US2646382A (en) Anthelmintic compositions
Kolář et al. Whole-Body Skeletal Metabolic Response on Local Skin Burns
US2143324A (en) Diuretic composition
Cristol et al. Toxicity of DDT isomers to some insects affecting man
US2768113A (en) Therapeutic composition of procaine and adrenaline precursor
US2098976A (en) Medicinal preparations containing metal compounds of decomposition products of nucleoproteins
US2635102A (en) Boron derivatives of ascorbic acid